We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
By Adriano Marchese
AstraZeneca PLC (AZN.LN) said Friday that its drug Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in Phase 3 Olympus and Rockies trials.
The drugmaker said the results of the global Phase 3 program as well as other data will form part of a regulatory submission in the U.S., which is anticipated in the fourth quarter of 2019.
Roxadustat is currently approved in China for the treatment of anemia in patients with CKD, regardless of whether they require dialysis, the company said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 08, 2019 02:33 ET (07:33 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions